ATTO
HOLD / NEUTRALNeutralComposite
46.80
Technical
49.70
Fundamental
44.90
Rank
—
Price
21.40
Hurst
—
As of
Sep 1, 2026
Daily
Attovia Therapeutics, Inc.
HealthcareBiotechnologyAttovia Therapeutics is a clinical-stage biopharmaceutical firm developing treatments for immune-mediated diseases using its ATTOBODY platform, which creates biparatopic fusion proteins targeting multiple disease pathways. Its pipeline includes candidates for chronic itching conditions, atopic dermatitis and other inflammatory skin disorders, and inflammatory bowel disease, with mechanisms targeting cytokines and cellular adhesion molecules. The company was founded in 2022 and operates from San Carlos, California.
Market cap
$693.4M
P/E (trailing)
—
P/E (forward)
-6.38
PEG ratio
—
Dividend yield
0.00%
Beta
—
52w range
12.94 – 28.00
Return on equity
—
Profit margin
0.00%
Revenue growth
—
Earnings growth
—
Price history
1Y: 15.19 (-30.6%) · range 13.73–25.55
Cycle position
6/ 100 cycle scoreENTRY ZONE
ENTRYAPPROACHMID-BULLNEAR-TOPEXIT
entry readiness 80 · GOOD SETUP · exit proximity 0
Conviction
45/ 100 · maturity 0%
Buildup.332
EMA entry setup.4280
Fundamentals.2545
Volume profile
POC
17.91
Price vs POC
-15.2%
Overhead supply
83%
Runway
+13.9%
Value area 16.55–24.08 · 83% of 62d volume overhead · heavy supply
Contributing sources
No source detections in the last 21 days.
Forward returns
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | -29.05% | +5.58% | mature |
| 40d | -42.85% | +5.58% | 35/40d |